In this prospective study, we identified two key findings: (1) Long-term treatment with nusinersen effectively improved motor function in adult SMA patients across all subtypes and enhanced daily living abilities in patients with SMN2 copy number > 3 and ambulant. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.